Celon Pharma S.A. (FRA:8RP)

Market Cap	232.50M -18.4%
Revenue (ttm)	59.93M +24.9%
Net Income	24.85M
EPS	0.46
Shares Out	n/a
PE Ratio	9.15
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	4.240
Previous Close	4.230
Day's Range	4.240 - 4.240
52-Week Range	4.055 - 5.770
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 18, 2026

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 560
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8RP

Financial Performance

In 2025, Celon Pharma's revenue was 242.21 million, an increase of 17.83% compared to the previous year's 205.55 million. Losses were -79.36 million, 130.4% more than in 2024.

Financial numbers in PLN

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error